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ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) has become a global pandemic, affecting 
millions of people. However, the relationship between COVID-19 and acute cerebrovascular 
diseases is unclear. 
Aims: We aimed to characterize the incidence, risk factors, clinical-radiological manifestations and 
outcome of COVID-19-associated stroke.
Methods: Three medical databases were systematically reviewed for published articles on acute 
cerebrovascular diseases in COVID-19 (December 2019-September 2020). The review protocol 
was previously registered (PROSPERO ID=CRD42020185476). Data were extracted from articles 
reporting 5 stroke cases in COVID-19. We complied with the PRISMA guidelines, and used the 
Newcastle–Ottawa Scale to assess data quality. Data were pooled using a random-effects model. 
Summary of review: Of 2,277 initially identified articles, 61 (2.7%) were entered in the meta-
analysis. Out of 108,571 patients with COVID-19, acute CVD occurred in 1.4% (95%CI: 1.0-1.9). 
The most common manifestation was acute ischemic stroke (87.4%); intracerebral haemorrhage 
was less common (11.6%). Patients with COVID-19 developing acute cerebrovascular diseases, 
compared to those who did not, were older (pooled median difference=4.8 years; 95%CI:1.7-22.4), 
more likely to have hypertension (OR=7.35; 95%CI:1.94-27.87), diabetes mellitus (OR=5.56; 
95%CI:3.34-9.24), coronary artery disease (OR=3.12; 95%CI:1.61-6.02), and severe infection 
(OR=5.10; 95%CI:2.72-9.54). Compared to individuals who experienced a stroke without the 
infection, patients with COVID-19 and stroke were younger (pooled median difference=-6.0 years; 
95%CI:-12.3 to -1.4), had higher NIHSS (pooled median difference=5; 95%CI:3-9), higher 
frequency of large vessel occlusion (OR=2.73; 95%CI:1.63-4.57), and higher in-hospital mortality 
rate (OR=5.21; 95% CI:3.43-7.90).
Conclusions: Acute cerebrovascular diseases are not uncommon in COVID-19, especially in those 
whom are severely infected and have pre-existing vascular risk factors. The pattern of large vessel 
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occlusion and multi-territory infarcts suggest that cerebral thrombosis and/or thromboembolism 
could be possible causative pathways for the disease. 
KEYWORDS 
Stroke, COVID-19; SARS-CoV-2; Acute cerebrovascular disease, hemorrhagic stroke 
Introduction
In December 2019, several cases of unexplained pneumonia were diagnosed in Wuhan, China, and 
then also diagnosed in other regions of the world, creating a global pandemic. Coronavirus Disease 
2019 (COVID-19) is caused by a severe acute respiratory syndrome (SARS)-like coronavirus 
(SARS-CoV-2). At the time of writing, the pandemic had affected more than 210 countries, with 
over 29 million confirmed cases, and over 900,000 fatalities(1). In most patients the disease is 
characterized by fever, dry cough, dyspnoea, and hypoxia with interstitial pneumonia features on 
chest XRay or computed tomography (CT) scan(2, 3). However, COVID-19 is not just a respiratory 
disease and can affect other organs, including the brain.
While several studies have highlighted a reduction in stroke admissions registered during the acute 
phase of the pandemic(4), there are accumulating reports of acute cerebrovascular disease (CVD) 
complicating COVID-19, including both acute ischemic stroke (AIS) and intracerebral haemorrhage 
(ICH)(5, 6). Previous reviews have shown an association between a past history of CVD and 
increased severity and mortality of COVID-19(7, 8); others papers have reviewed the spectrum of 
neurological manifestation in COVID-19(9-11). However, whether COVID-19 may be considered a 
risk factor for stroke is still not established. Similarly, little is known about any specific 
characteristics of COVID-19 associated stroke.
We performed a systematic review and meta-analysis to investigate the relationship between 
COVID-19 and stroke. We used the data to ask the following questions: 1) What is the incidence of 
stroke in COVID-19 patients? 2) What are the risk factors for stroke in COVID-19 patients? 3) 
What are the characteristics of stroke in COVID-19 patients? 4) What is the outcome of stroke in 
COVID-19 patients? Finally, we discuss a range of the possible pathogenic mechanisms linking 
COVID-19 with stroke.
Methods
Search Strategy and Selection Criteria 
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In this systematic review and meta-analysis, we searched published literature that provided 
evidence of acute cerebrovascular manifestations in COVID-19. The review protocol was registered 
before starting on PROSPERO  
(https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=185476) and 
recommendations of the PRISMA statement were applied(12, 13).
Two medical (MEDLINE accessed from PubMed, and Scopus) and one pre-prints (MedRxiv) 
database were systematically reviewed for related articles from December 01, 2019 to September 
14, 2020. In all electronic databases, our search criteria were based on predefined search terms 
(available in eMethods, Supplementary material). To ensure literature saturation, reference lists of 
included studies and relevant reviews identified through the search were scanned by the authors. 
We included studies with information on new-onset cerebrovascular event(s) in patients with 
confirmed SARS-CoV-2 infection. Case reports and series, correspondence with relevant clinical 
data, case-control and cohort studies were included for further review. We excluded studies that 
were reported as abstract-only (with no full-texts available), non-English articles, studies conducted 
on animal subjects, studies on paediatric populations, and repeat publications on the same patient 
cohorts. 
Two authors (SN, RdG) participated in each phase of the review independently (screening, 
eligibility, and inclusion). They screened titles and abstracts, obtained full reports for all titles that 
appeared to meet the eligibility criteria or where there was any uncertainty, and decided whether 
these meet the inclusion criteria. All excluded studies were documented with reasons for exclusion. 
Any disagreement was resolved through consensus.  
Case reports and observational studies were included in the quantitative analysis (meta-analysis) if 
they reported at least five cases of COVID-19 patients developing acute CVD. The list of the 
extracted variables for each included study was prespecified, and is available in eMethods, 
Supplementary material. The quality assessment for each observational study included in the meta-
analysis was performed using the adapted Newcastle–Ottawa Scale (NOS)(14). 
Data analysis
All analyses were performed using R v4.0.2. Median values of continuous traits were aggregated 
using the median of medians approach, and the median of the difference of the median between 
two-groups was calculated via the metamedian package(15, 16). To maximise the number of studies 
available for us to analyse, we also incorporated mean differences between two groups as 
simulations have shown that the median of the difference of medians method is robust when most 
Commented [CLJ1]:  What does this mean? Could you 
clarify? 
Page 7 of 24








of the studies considered report the sample median of the outcome(16). An approximate 95% 
confidence interval (95% CI) of the pooled value was calculated by inversing the sign test. Binary 
traits were analysed using the meta package. We used a generalised linear mixed model to calculate 
the weighted average proportion and 95% CIs for individual studies were calculated using the 
method proposed by Clopper-Pearson(17). Odds ratios (and their associated 95% CIs) were 
calculated and combined via random effect meta-analysis (inverse variance method) using the 
metabin function. Heterogeneity of effect sizes was quantified using I2 and Tau2 (DerSimonian-
Laird estimator).
Results
The literature search identified 2,277 publications, including 770 from Pubmed, 1359 from Scopus 
and 148 from MedRxiv; 371 were duplicates and removed. Therefore 1,906 unique papers were 
identified, and after abstract review 193 were selected for full-text review (eFigure 1). Of these, 138 
met inclusion criteria. Seven additional papers were identified from reference lists. Therefore, 145 
papers were included in the systematic review; these comprised 57 case reports, 51 case series, 4 
case-controls studies and 33 cohort studies. Of these, 61 articles (24 case series, 4 case-controls and 
33 cohort studies) reported at least 5 stroke cases in COVID-19 patients and were included in meta-
analysis. The complete reference list for the included papers is available in eTable 1 and eTable 2. 
The quality assessment of the 33 included cohort studies is reported in eTable 3, and revealed a 
high quality in 14/33 (42%) records. 
Incidence of acute CVD in COVID-19 patients
Twenty-four observational cohort studies reported the incidence of acute CVD in COVID-19 
patients ranging from 0.4% to 8.1% (Figure 1). Across these studies, there were a total of 108,571 
COVID-19 patients, of which ischemic or hemorrhagic stroke was reported in 1,106 patients, 
yielding on meta-analysis an overall pooled incidence of acute CVD of 1.4% (95%CI:1.0-1.9). 
These studies were conducted in different countries with varying ethnic demographics. Analysis of 
acute CVD incidence showed geographical variation, with a higher incidence reported in Asia 
(3.1%; 95%CI:1.9-5.1) than in Europe (1.2%, 0.7-1.9) and North America (1.1%; 95%CI:0.8-1.4) 
(Figure 1). We performed a sensitivity analysis, limiting the analysis to high-quality data only, 
which gave a similar pooled incidence of new cerebrovascular diseases in COVID-19 patients of 
1.3% (95%CI:0.9-1.8). 
Risk factors for stroke incidence in COVID-19 patients 
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Four studies were available to compare clinical characteristics of COVID-19 patients with CVD 
(n=113) and without CVD (n=11683) (Figure 2 and Suppl. Figure e2). Compared with COVID-19 
patients without CVD, COVID-19 patients that developed acute CVD were older (pooled median 
difference for age=4.8 years; 95%CI=1.7-22.4); there was no sex difference. Stroke risk in COVID-
19 was higher in patients with cardiovascular risk factors, with patients developing CVD having 
greater likelihood of hypertension [81/113 vs 2392/11683; OR=7.35 (95%CI:1.94-27.87)], diabetes 
mellitus [52/113 vs 1489/11683; OR=5.56 (95%CI:3.34-9.24)] and coronary artery disease [18/38 
vs 508/2181; OR=3.12 (95%CI:1.61-6.02)]. There was no significant difference in rates of smokers 
versus non-smokers [23/71 vs 560/9374; OR=3.69 (95%CI:0.47-29.23)]. Stroke in COVID-19 
patients was associated with more severe infectious disease [33/49 vs 571/2389; OR=5.10 
(95%CI:2.72-9.54)] (Figure 2 and Suppl. Figure e2). Both groups showed high level of D-dimer, 
without significant differences in median values (pooled median difference=1248 μg/L; 95%CI: -
5600;6400).
Characteristics of COVID-19 patients developing acute CVD
Fifty studies were available for meta-analysis of clinical characteristics of COVID-19 patients with 
acute CVD. Demographics, vascular risk factors, COVID-19 characteristics, and blood 
investigations are presented in Table 1. Median age was 65.3 (61.4-67.6) years and the majority 
were male (62.4%, 1141/1912). Vascular risk factors were common: hypertension (62.2%, 
1111/1731), diabetes mellitus (36.7%, 612/1696) and dyslipidemia (25.2%, 625/947). The majority 
of patients manifested COVID-19 symptoms at stroke onset (84.1%, 350/453); the median delay of 
stroke from COVID-19 symptoms onset was 8.8 (6.3-11.6) days. When analyzing the clinical 
reason for admission (COVID-19 symptoms versus stroke symptoms), we found that neurological 
symptoms related to stroke represented the reason for hospital admission in 37.7% (414/1063) of 
patients. Sixty-one percent (609/1032) of patients suffered from a severe form of COVID-19; 
radiological signs of pneumonia were detected in 86.7% (198/246) patients, and signs of pulmonary 
embolism in 14.8% (9/61). Laboratory investigations showed elevated median D-dimer (3720 μg/L) 
and fibrinogen (459 mg/L) levels. Information on antiphospholipid antibodies was available in 87 
stroke cases; among these, 17.2% tested positive for IgM/IgG anti-cardiolipin or anti-β2-
glycoprotein I antibodies. 
Stroke subtype, neuroimaging features and outcome of COVID-19 patients developing acute CVD
We identified 1329 (87.4%) COVID-19 patients developing AIS, and 180 (11.6%) ICH (Table 1). 
The median NIHSS score in patients with AIS was 15 (13-18), and a large vessel occlusion pattern 
of stroke was described in 79.6% (597/1189). Simultaneous involvement of different vascular 
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territories in AIS was frequent (42.5%, 115/274) (Table 2). Details regarding acute stroke treatment 
were available for about 1200 patients with AIS: 19.1% (236/1205) received intravenous 
thrombolysis, whereas 25.9% (238/1223) underwent endovascular thrombectomy.
Based on data from 829 cases, the most common stroke mechanism in AIS was cryptogenic 
(44.7%, 242/829), followed by cardioembolism (21.9%, 167/829), and large vessel atherosclerosis 
(10.6%, 112/819). Small artery stroke was infrequently reported (3.3%, 43/819). 
Out of 102 patients with ICH, 44.1% showed a strictly lobar hematoma, and in 18.5% (10/61) the 
volume of hematoma led to intracranial herniation (Table 2).
Up to 44 studies reported data on discharge outcomes of patients with stroke and COVID-19 (Table 
1). Out of the 1655 patients with information on mortality, 31.5% (521) suffered in-hospital death, 
whereas 19.1% (379/1315) were discharged home, and 25.7% (228/744) were discharged to 
rehabilitation facilities.
Stroke features in COVID-19 patients compared with non-COVID-19 patients with stroke
Eleven studies were analyzed to compare stroke characteristics in patients with and without 
COVID-19 (Suppl.Table e4). Patients with COVID-19 and stroke were younger than patients with 
stroke without infection (pooled median difference for age= -6.0; 95%CI=-12.3;-1.4), and female 
sex was less frequently affected [150/395 vs 773/1670; OR=0.71 (95%CI:0.51-0.99)]. Patients were 
less likely to have hypertension [257/385 vs 835/1128; OR=0.65 (95%CI:0.45-0.96)] and previous 
stroke [11/146 vs 159/720; OR=0.34 (95%CI:0.18-0.63)]; there was no significant difference in 
other cardiovascular risk factors (diabetes mellitus, dyslipidemia, smoking, coronary artery disease 
and atrial fibrillation). Acute ischemic stroke due to large vessel occlusion was more common in 
COVID-19 cases [127/251 vs 613/1031; OR=2.73 (95%CI: 1.63-4.57)] (Figure 2). Stroke severity 
was higher in patients with stroke and COVID-19 (pooled median difference for NIHSS score 5; 
95%CI=3;9), and cryptogenic stroke was more common (26/41 vs 56/177; OR=3.40, 95% CI:1.16-
10.00) (Supp Figure e3). Despite receiving acute stroke treatments (intravenous thrombolysis and 
thrombectomy) in similar proportions, individuals with stroke and COVID-19 infection showed 
higher in-hospital mortality (144/432 vs 191/1643; OR=5.21, 95% CI:3.43-7.90) (Figure 2).
Discussion
In this systematic review and meta-analysis investigating the characteristics and outcomes of 
patients infected with SARS-CoV-2 and suffering a stroke, we found a pooled incidence of 1.5% of 
acute CVD in COVID-19. Individuals with COVID-19 who experienced concomitant stroke were 
Page 10 of 24






more likely to be older, have pre-existing cardiovascular comorbidities, and severe infection. Most 
patients had been admitted with COVID-19 symptoms, with stroke occurring a few days later. 
Ischemic stroke was the commonest stroke subtype, and was frequently characterized by multiple 
cerebral infarctions and cryptogenic etiology. In comparison to strokes without COVID-19, people 
with CVD and COVID-19 were younger, suffered from more severe stroke, and stroke was more 
often caused by large artery occlusion.  
There was variation in stroke incidence rates among individuals with COVID-19 across the 
included studies. This may reflect differences in the population studied; highest rates were reported 
in cohorts of critically ill patients(18, 19), and in studies analyzing neurological complications of 
COVID-19(20-22).  It may also reflect differences in healthcare system organization, and intensity 
of neurologic screening. Overall, we recorded the highest stroke rates in Asian populations(18, 23). 
The severity of the infective disease consistently emerged as an important risk factor for stroke 
across different studies(18, 23, 24). Moreover, we found that people with COVID-19 developing a 
stroke were older than infected patients without stroke. This may partly explain the higher 
proportion of vascular risk factors that characterized the cerebrovascular group.
Comparison with non-infected patients with stroke showed that individuals with COVID-19 who 
developed stroke were significantly younger. There have been several reports on young patients 
without vascular risk factors admitted for large-artery stroke during the pandemic(25-27). Similarly, 
other studies highlighted a younger age of patients undergoing thrombectomy compared to the pre-
pandemic period(28-30). Our pooled results confirmed these reports, and suggest a particular 
profile of COVID-19-associated strokes, characterized clinically by severe NIHSS and poor 
outcome, and radiologically by large artery occlusion and multiple arterial territory involvement. 
These strokes were more commonly labeled as cryptogenic, compared to contemporary and 
historical stroke controls(27). These findings from the comparison between strokes with and 
without COVID-19 could suggest that some mechanisms directly related to COVID-19 have a role 
in the occurrence of stroke, and explain the characteristic profile of stroke in infected patients. 
Large artery occlusion in COVID-19 may be primarily due to cardioembolism or paradoxical 
embolism, and less often due to large artery atherosclerosis and plaque rupture(31), thus explaining 
the occurrence of stroke among young people without vascular risk factors, in individuals with high 
levels of D-dimer or other signs of hypercoagulability, or in patients with pulmonary embolism and 
venous thrombosis(19).
An important question is whether stroke occurring in individuals with COVID-19 is causally 
related, or represents an incidental association due to COVID-19 infection being widespread in the 
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community. The occurrence of stroke in those with COVID-19 does not provide direct evidence of 
causality between the two diseases. As with all observational studies, residual confounding may be 
an explanation, as a substantial proportion of the patients hospitalized with COVID-19 and stroke 
exhibit several vascular risk factors; also, some COVID-19-related factors, such as less controlled 
vascular risk factors and mental stress, may also contribute to stroke. However, a number of lines of 
evidence suggest that COVID-19 may be a trigger or risk factor for stroke at least in a proportion of 
cases. Firstly SARS-CoV-2 infection appears more likely to cause thrombotic vascular events, 
including stroke, than other coronavirus and seasonal infectious diseases, with a 7.6-fold increase in 
the odds of stroke with COVID-19 compared with influenza(24). Secondly, the characteristic 
pattern of stroke in individuals with COVID-19, with an increased proportion of large artery 
occlusion, infarction involving multiple territories, and increased cryptogenic aetiology, suggests a 
causal relationship in at least a proportion of patients. 
Previous reports have been published with the attempt to clarify the relationship between stroke and 
COVID-19. These included narrative reviews(32, 33), systematic reviews(9-11, 34) and meta-
analyses(34, 35). While some authors have focused on the relationship between personal history of 
CVD and COVID-19(7, 8), we studied the incidence and risk factors for the occurrence of new 
CVD in concomitant SARS-CoV2 infection, searching for a specific profile of COVID-19-
associated stroke. We found a similar rate of stroke incidence in COVID-19 compared to previous 
reports, but included a higher number of cohort studies(34, 35). We provide a comprehensive 
picture of the clinical, biochemical and radiological features of stroke in COVID-19; in comparison 
to other reviews(36, 37), this was done after excluding case reports and small case series (which 
may be biased through focusing on particularly unusual cases), thus strengthening the solidity of 
our results. Core novelties of our investigation are synthesis of evidence on the topic of risk factors 
for stroke in people with COVID-19 as well as the comparison of stroke characteristics between 
infected and non-infected patients, both of which are vital to on-going clinical care and 
management during the current pandemic.
Our results may have important clinical implications. We demonstrated that stroke might 
complicate the course of COVID-19, with older and severely infected patients being at higher risk. 
Even if the incidence of stroke in COVID-19 population was less than 2%, the scale of the COVID-
19 pandemic means that many thousands of people could potentially be affected by this 
complication globally. Therefore, clinicians should be vigilant for signs and symptoms of acute 
CVD in individuals with COVID-19 to ensure appropriate clinical interventions. Special attention 
should be paid in intubated or sedated patients, in whom awareness of potential neurological signs 
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is important, for example by monitoring of Glasgow Coma Scale and pupil reaction, and in patients 
with abnormal elevation in coagulation laboratories or other thrombotic complications. Moreover, 
even if though the majority of strokes occurred after a few days of COVID-19 symptoms onset, we 
found that neurological symptoms represented the reason of hospital admission in more than one 
third of people with COVID-19 and stroke. These patients might have mild respiratory symptoms, 
or be completely asymptomatic, with subsequent important implications for stroke care re-
organization. In fact, all patients with stroke in the pre-hospital setting should be treated as potential 
COVID-19 cases until the results of COVID-19 screening in the hospital are negative, and for 
patients with suspected or confirmed infection a protected stroke pathway should be adopted.
Mechanisms of stroke in individuals infected with COVID-19
The mechanisms of cerebrovascular manifestations in people with COVID-19 are likely 
multifactorial. They could be related to conventional stroke mechanisms, with COVID-19 acting as 
a trigger(38, 39). Alternatively, they could be directly caused by SARS-CoV-2 infection, through 
specific pathophysiological mechanisms leading to both ischemic and hemorrhagic stroke (Figure 
3).
Ischemic stroke mechanisms in COVID-19 
Activation of the coagulation pathway with elevated D-dimer and fibrinogen is a common feature 
of many individuals with severe COVID-19 infection. This coagulopathy, termed “sepsis-induced 
coagulopathy” (SIC), is related to the infection-induced systemic inflammatory response and may 
contribute to the increased risk of thrombosis and stroke(40, 41). Also, the presence of 
antiphospholipid antibodies (aPL), including IgA anticardiolipin antibodies and IgA and IgG beta 2 
glycoprotein I antibodies, has been reported in severely infected patients with multiple cerebral 
infarcts(23, 42). Hypercoagulation could lead to ischemic stroke promoting venous 
thromboembolism and paradoxical embolism; this could explain stroke from large vessel occlusion 
in young people without vascular risk factors, where plaque rupture or in situ thrombosis seem less 
likely(31). 
COVID-19, similar to other coronaviruses, uses the angiotensin-converting enzyme 2 (ACE-2) 
receptor to enter the cells(43). This receptor is expressed in the lungs, heart, kidneys, and vascular 
endothelium. Direct viral invasion of endothelial cells causes an inflammation or “endothelitis” 
which has been proposed as one of the substrates for the thrombotic complications of COVID-
19(44). Moreover, binding of SARS-CoV-2 to ACE-2 receptor causes a depletion of its availability 
through endocytosis, and ultimately a down-regulation of the renin angiotensin system (RAS)(45). 
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In fact, the unopposed generation of Angiotensin II, no more counterbalanced by Angiotensin (1-7) 
worsens lung injury, and is also responsible for endothelial dysfunction in organs like the heart and 
brain. This could result into increased sympathetic activity, loss of blood pressure autoregulation, 
and vasoconstriction with subsequent organ ischemia(46).
The continuous and uncontrolled activation of the immune system caused by the viral infection, 
with subsequent excessive cytokine release or “cytokine storm”, has been implicated in brain 
damage during COVID-19. Cytokines/chemokines promote atherosclerosis, plaque rupture, and 
superimposed thrombosis(47). Together with endothelial injury, they can up-regulate tissue factor 
expression and further promote a pro-thrombotic state(48).
Various manifestations of myocardial injury have been described, including viral myocarditis, 
myocardial dysfunction related to the cytokine storm, CAD caused by oxygen supply and demand 
mismatch, and stress cardiomyopathy due to the stimulation of the sympathetic nervous system(49, 
50). All these mechanisms may lead to cardiac arrhythmias and intracardiac thrombus formation, 
possibly exacerbated by the hypercoagulable state, and could increase cardioembolic stroke.
Finally, some individuals with COVID-19 may be particularly susceptible to cerebrovascular injury 
from hypoxemia(51).  In those with pre-existing intracranial stenosis, for example, hypoxemia could 
lead to infarction due to a mismatch between oxygen supply and demand(52). Similarly, cerebral 
hypoperfusion secondary to the downregulation of the RAS could increase the risk of both large 
vessel and SVD infarction, with a typical border-zone distribution(53, 54).
Hemorrhagic stroke mechanisms in COVID-19 
Our review highlighted that COVID-19-related hemorrhagic strokes are much less common than 
ischemic strokes. Whether the COVID-19 infection and intracerebral hemorrhage are casually 
related in these cases is unclear. However, some mechanisms mediating the increased risk of 
ischemic stroke in patients with COVID-19 could also play a role in promoting intracranial 
bleeding(55, 56).
The affinity of the SARS- CoV-2 for ACE2 receptors could allow the virus to directly damage 
intracranial arteries, causing vessel wall rupture. Also,  downregulation of RAS may rise blood 
pressure and put patients already diagnosed with hypertension at higher risk for hemorrhagic 
stroke(57). Older individuals, affected by age-related ACE2 deficiency, might be particularly 
exposed to risk of ICH in this setting.
The integrity of blood brain barrier (BBB) could be impaired by the massive release of cytokines 
and proteases that accompanies the immune response to the SARS- CoV-2 infection(57, 58). 
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Besides ICH, the BBB breakdown could explain the cases of hemorrhagic posterior reversible 
encephalopathy syndrome (PRES) and hemorrhagic transformation of ischemic strokes that have 
been reported in those with COVID-19(59).
Also, SARS-CoV-2 infection could be associated with a consumption coagulopathy related to 
fibrinogen depletion (either from metabolic acidosis or disseminated intravascular coagulation), 
which may increase the risk of ICH(38). 
Finally, perivascular micro-hemorrhages with cerebral microbleeds visible on susceptibility 
weighted MRI have been described in a few individuals with severe COVID-19 and neurologic 
complications(60). Their location in the corpus callosum and the subcortical and deep white matter 
was similar to the anatomical distribution seen in patients with hypoxic respiratory failure and 
sepsis, suggesting a potential role of cerebral hypoxia in brain injury in severe COVID-19(60).
Limitations
Given the recency of the pandemic, the findings from this review should be considered preliminary. 
Assumptions on the stroke incidence amongst people with COVID-19 were mostly based on small, 
single-centre observational studies, and therefore should be regarded with caution. Moreover, the 
number of cohort studies providing information on stroke control groups was limited, reducing the 
reliability of estimates of stroke risk in individuals infected with COVID-19. Also, the results on 
stroke etiologies and stroke outcome in COVID-19 might be affected by the fact that some patients 
were still hospitalized at the time of publication, which may limit the assessment of the natural 
course of the disease. Finally, we acknowledged that the meta-analysis results could be hampered 
by the heterogenous quality of the included papers, some of them rated as only moderate-quality. 
Conclusions 
We found 1.5% of individuals with COVID-19 suffered acute CVD. This risk was highest in those 
most severely infected and those with pre-existing vascular risk factors. The pattern of stroke 
differed from that in a non-COVID-19 stroke population. Most strokes were ischemic, and there 
was an increase in large vessel occlusion and multiple territory infarcts suggesting that increased 
thrombosis and thromboembolism could be important. Further studies are required to provide more 
robust estimates of the increase in stroke resulting from COVID-19 and to elucidate the precise 
pathophysiology linking COVID-19 to risk of CVD.
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Figure 1. Pooled analysis of the proportion of COVID-19 patients developing acute CVD, 
presented for continents. 
Figures 2. Risk factors for acute CVD in COVID-19 patients, showing the distributions of female 
sex (Sex_F), hypertension (HTN), diabetes (DM), coronary artery disease (CAD), and severe 
COVID-19 (COVID severe) in infected patients with and without stroke. Stroke characteristics of 
patients with and without COVID-19 are also showed, presenting the distribution of AIS from large 
vessel occlusion, the rates of acute stroke treatments, and of in-hospital deaths between the two 
groups.
Figure 3. Overview on the possible stroke mechanisms in COVID-19 patients.
This figure was created using Servier Medical Art templates, which are licensed under a Creative Commons 
Attribution 3.0 Unported License; https://smart.servier.com
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Table 1. Demographics, clinical characteristics, laboratory variables and outcome of COVID-19 
patients developing acute cerebrovascular disease (CVD). Only studies reporting at least 5 patients 
with new-onset of CVD and COVID-19 were included in the pooled analysis. 
Variable
N of valid 
studies
N of events Pooled values°
Demographics
Age, years (median [95% CI]) 50 1767 65.3 [60.4; 67.6]
Sex, female 50 771/1912 37.6 [33.2; 42.2]
Vascular risk factors
Hypertension 45 1111/1731 62.2 [55.9; 68.1]
Dyslipidemia 37 625/947 25.2 [17.3; 35.1]
Diabetes mellitus 44 612/1696 36.7 [32.1; 41.6]
Atrial fibrillation 37 225/1326 13.9 [9.7; 19.5]
Smoking 35 246/1491 9.6 [5.9; 15.3]
Personal history of stroke 29 113/1314 8.0 [4.8; 13.0]
Coronary artery disease 30 254/1382 15.9 [12.1; 20.6]
Type of acute CVD
Acute ischemic stroke 28 1329/1559 87.4 [80.1; 92.3]
Transient ischemic attack 28 15/1559 0.1 [0.0; 2.1]
Intracerebral haemorrhage 28 180/1559 11.6 [10.1; 13.3]
Cerebral venous thrombosis 28 25/1559 0.5 [0.1; 2.2]
COVID-19-related clinical variables
COVID-19 symptoms present at stroke onset 32 350/453 84.1 [73.7; 91.0]
COVID-19 to stroke onset delay, day (median) 24 996 8.8 [6.3; 11.6]
Stroke as reason for admission 36 414/1063 37.7 [21.2; 57.6]
Severe disease 27 609/1032 60.5 [50.1; 70.0]
Intubation at stroke onset 10 7/66 2.9 [0.2; 35.1]
Pneumonia 14 198/246 86.7 [71.7; 94.3]
Pulmonary embolism 6 9/61 14.8 [7.9; 26.0]
Laboratory variables
D-dimer, μg/L (median [95% CI]) 29 937 3720 [1458; 5535]
Fibrinogen, mg/L (median [95% CI]) 14 702 459 [361; 486]
Therapeutic anticoagulation at stroke onset 24 94/471 9.6 [4.5; 19.4]
Antiphospholipid antibodies positive 7 17/87 17.2 [7.0; 36.6]
Lupus anticoagulant positive 4 9/30 26.8 [5.5; 69.6]
Discharge outcomes
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In-hospital death 44 521/1655 31.5 [27.3; 36.0]
Discharged home 30 379/1315 19.1 [13.2; 26.8]
Discharged to rehabilitation 25 228/744 25.7 [18.9; 33.8]
Not discharged at time of publication 20 170/901 11.1 [4.7; 23.8]
°Pooled values are presented as median (and 95% confident interval, CI) for continuous variables and as 
proportion (and 95% CI) for categorical variables.
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Table 2. Clinical and radiological characteristics of COVID-19 patients developing acute ischemic 
stroke and intracerebral haemorrhage. Only studies reporting at least five patients with new-onset of 
CVD and COVID-19 were included in the pooled analysis. 
Variable
N of valid 
studies
N of events Pooled values°
Acute ischemic stroke in COVID-19 
Clinical variables
NIHSS on admission (median [95% CI]) 29 1202 15 [13-18]
Vigilance impairment at stroke onset 13 172/693 26.4 [14.6; 43.0]
Radiological variables
Vascular territory, anterior 22 278/394 81.7 [70.2; 89.4]
Multiple infarction 15 115/274 42.5 [31.3; 54.5]
Large vessel occlusion 35 597/1189 79.6 [64.5; 89.3]
Acute stroke treatment
Intravenous thrombolysis 34 236/1205 19.1 [12.4; 28.2]
Endovascular treatment - thrombectomy 36 238/1223 25.9 [13.5; 44.1]
Successful recanalization after thrombectomy 13 85/98 87.1 [76.2; 93.5]
Stroke etiology
Cardioembolism 21 167/829 21.9 [16.5; 28.4]
Large artery atherosclerosis 20 112/819 10.6 [6.5; 16.8]
Small vessel disease 20 43/819 3.3 [1.3; 7.8]
Cryptogenic stroke 21 242/829 44.7 [27.1; 63.9]
Intracerebral haemorrhage in COVID-19 
Intraparenchymal hematoma, lobar 12 45/102 44.1 [34.7; 54.0]
Bilateral location 8 7/36 20.4 [8.2; 42.4]
Intracranial herniation 7 10/61 18.5 [6.5; 42.4]
°Pooled values are presented as median (and 95% confident interval, CI) for continuous variables and as 
proportion (and 95% CI) for categorical variables.
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